← Every firm
Mylan Institutional, Inc. FDA Recalls
8 recalls on file across drugs, 0 of them Class I and 8 still open. This firm is not matched to a listed company.
Newest first
Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.
| Product |
|---|
| Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tabletClass IIMar 7, 2025Super-Potent Drug: Out of specification potency results were |
| Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tabletsClass IIMar 7, 2025Super-Potent Drug: Out of specification potency results were |
| Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets Class IINov 19, 2024Subpotent and Superpotent Drug |
| Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets Class IINov 19, 2024Subpotent and Superpotent Drug |
| Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets Class IINov 19, 2024Subpotent and Superpotent Drug |
| Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets Class IINov 19, 2024Subpotent and Superpotent Drug |
| Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets Class IINov 19, 2024Subpotent and Superpotent Drug |
| Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets eaClass IINov 19, 2024Subpotent and Superpotent Drug |